МАРКЕТИНГОВІ ДОСЛІДЖЕННЯ ЛІКАРСЬКИХ ЗАСОБІВ ДЛЯ ЗАСТОСУВАННЯ У ДЕРМАТОЛОГІЇ НА ФАРМАЦЕВТИЧНОМУ РИНКУ УКРАЇНИ (ПОВІДОМЛЕННЯ I)

Abstract

Keywords: pharmaceutical, marketing research, medicinal product, marketing researches, active pharmaceutical ingredient, drug formulation, pharmaceutical market, wound process. The purpose of the study was to conduct complex marketing research of the current condition of the pharmaceutical market for use in dermatology to compose the well-balanced combination drugs (CD) for wound healing. Materials and methods: Conduct of complex marketing researches involved the use of general scientific, systematic, and survey research methods of informational search: bibliographical, document retrieval, content analysis, comparative approach, and system-oriented analysis. Results. The current condition of the domestic pharmaceuticals market was analysed and summed up for the availability of the Group D medicinal products according to Anatomical Therapeutic Chemical (АТС) classification system. Market dependency on import medicinal products was identified (import products share amounts to 57,8% of the market). The trends which reflect the innovation activity of the domestic pharmaceutical industry were presented in the findings. Prevailing (based on its specific density) medicinal products subgroups according to ATC classification «Corticosteroids for use in dermatology» (26,3%), «Anti-fungals for use in dermatology» (18,1%), «Antiseptics and Disinfectants» (14,1%), «Medicinal products for wound and ulcerous injuries healing» (12,7%), and «Antibiotics and chemotherapeutics» (11,5%). It was established that the main importers of the interested medicinal products groupare Germany (20,4%), India (16,2%), Poland (12,3%), Croatia (7,1%), Switzerland (6,3%), Belgium (5,2%), Austria (4,8%), and Hungary (4,2%). We found out that in the dermatology medicinal products segment, active pharmaceutical ingredients by their nature are mostly synthetic (88%), and by their composition, such medicinal products are mixed formulations with the subgroups market share between 58,5% – 76,3%. It was also shown that the optimal assortment range of modern combination drugs of dermatology medicinal products for 38 domestic producers is not yet reached. We paid attention to the perspective regarding the pharmaceutical development of new combination drugs for application therapy. Conclusions. The research of the effectiveness of different groups of medicinal products to wound healing on different stages, allowed us to conclude that the usage of imported combination effect medicinal products for wound healing is more cost-ineffective while the Ukrainian pharmaceutical market requires product differentiation and introduction of the new combined antimicrobial and anti- inflammatory effect medicinal products into production for wound healing and wound infection.